AZD2820 / AstraZeneca, Palatin Technologies - LARVOL DELTA

A microfluidic in vitro method predicting the fate of peptide drugs after subcutaneous administration. (PubMed, Int J Pharm) - "The results from MIS studies of the peptide drugs exenatide, pramlintide, vancomycin, polymyxin B, lanreotide, MEDI7219 and AZD2820 are compared with results from measurements with the commercially available SCISSOR system and in vivo absorption and bioavailability data from the literature. A correlation is found between the 1st order release rate constant determined with SCISSOR and ka for lanreotide (Autogel), exenatide and AZD2820. A mechanism relating the magnitude of ka to the peptides' charge is proposed."

Journal • Preclinical

AstraZeneca halts development of anti-obesity drug (Market Watch) - AstraZeneca decided to discontinue further development of an obesity drug, AZD2820 after a clinical trial for the treatment was halted as a man enrolled in the study became ill

Discontinued • Obesity